News & Trends - Pharmaceuticals

New partnership for clinical development of therapeutics for retinitis pigmentosa

Health Industry Hub | October 9, 2019 |
[Total: 1    Average: 4/5]

Lions Eye Institute (LEI) and PYC Therapeutics have entered into a commercial collaboration agreement to develop drugs for a leading cause of blinding eye disease. The commercial partnership will take the form of a special purpose vehicle, Vision Pharma Pty Ltd.

The Vision Pharma lead program combines PYC’s best-in-class delivery technology with LEIs novel RNA therapies to create a competitively differentiated drug to treat a leading cause of childhood blindness – Retinitis Pigmentosa. Vision Pharma intends to commence Investigational New Drug (IND)-enabling studies for this lead program in the first half of 2020. Successful IND-enabling studies will culminate in approval for testing in humans.

“The formation of Vision Pharma in WA is the culmination of combining decades of research into splice therapy (led by Sue Fletcher, Co-inventor), cell penetrating peptides (through PYC), data from the Australian Inherited Retinal Diseases Registry (established in the 1980s), and more recently developed local expertise in stem cell retinal disease modelling (LEI)” said Dr Fred K. Chen, co-inventor of the lead drug and head of LEI’s Ocular Tissue Engineering Laboratory.

This development will enable a potential drug to be delivered from discovery right through to the clinic, all driven from Perth, WA. “We look forward to the clinical development of therapeutics for Retinitis Pigmentosa and other degenerative retinal diseases” commented Professor Sue Fletcher, Chief of Research and Development at PYC Therapeutics and global leader in RNA Therapeutics.

Through this collaboration Vision Pharma’s lead drug candidate has already shown preliminary evidence that it can reverse the effects of Retinitis Pigmentosa in human cells. Figure 1 (attached) illustrates the effectiveness of combining PYC’s delivery technology (a Cell-Penetrating Peptide, or CPP) with Vision Pharma’s molecule (an Antisense Oligonucleotide, or ASO). Healthy retinal cells express the red cilia, whilst diseased cells do not. The treatment significantly increases the expression of these red cilia by the diseased patient cells, a key functional readout for drugs intending to rescue our target form of Retinitis Pigmentosa. The photographs attached clearly show that joining Vision Pharma;s ASO to PYC’s CPP increases both the amount of cells expressing cilia, and the length of these cilia above the naked ASO.

On the potential of this exciting collaboration, LEI Managing Director Bill Morgan said “LEI is proud to see one of its research developments now entering preclinical trials to treat the commonest form of Retinitis Pigmentosa, a previously untreatable blinding condition. Prof Fred Chen and Prof Sue Fletcher have been working on their genetic therapy and are partnering with PYC, using their transporter protein to deliver this novel therapy directly to the sick retinal cells. We are very excited about the possibility of being able to cure this form of blindness.”

You may also like Affordable medicines for over 500,000 Australians


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

Prime Minister’s Prize for Innovation awarded to cancer drug breakthrough

Health Industry Hub | October 21, 2019 |

The discovery and development of a breakthrough anti-cancer drug has seen four senior scientists from the Walter and Eliza Hall […]

More


News & Trends - Pharmaceuticals

Pharmacist prescribing on the way

Health Industry Hub | October 21, 2019 |

The Pharmaceutical Society of Australia (PSA) has welcomed the Pharmacy Board of Australia’s position statement on pharmacist prescribing which outlines the way […]

More


News & Trends - Medical Technology

Competitive grants to turn MedTech discoveries into clinical reality

Health Industry Hub | October 21, 2019 |

Cutting edge researchers and entrepreneurs can receive up to $1 million from the Morrison Government to develop their breakthrough medical […]

More


News & Trends - Pharmaceuticals

New discovery to reduce renal failure in patients with diabetic kidney disease

Health Industry Hub | October 21, 2019 |

Researchers from Monash University’s Central Clinical School in Australia have found that a drug that has already been tested on other […]

More